Abstract:Growth arrest DNA damage-inducible gene 45 beta (GADD45beta) has been known to regulate cell growth, apoptotic cell death, and cellular response to DNA damage. Down-regulation of GADD45beta has been verified to be specific in hepatocellular cancer (HCC) and consistent with the p53 mutant, and degree of malignancy of HCC. This observation was further confirmed by eight HCC cell lines and paired human normal and HCC tumor tissues by Northern blot and immunohistochemistry. To better understand the transcription regulation, we cloned and characterized the active promoter region of GADD45beta in luciferase-expressing vector. Using the luciferase assay, three nuclear factor-kappaB binding sites, one E2F-1 binding site, and one putative inhibition region were identified in the proximal promoter of GADD45beta from -865/+6. Of interest, no marked putative binding sites could be identified in the inhibition region between -520/-470, which corresponds to CpG-rich region. The demethylating agent 5-Aza-dC was used and demonstrated restoration of the GADD45beta expression in HepG2 in a dose-dependent manner. The methylation status in the promoter was further examined in one normal liver cell, eight HCC cell lines, eight HCC tissues, and five corresponding nonneoplastic liver tissues. Methylation-specific polymerase chain reaction and sequencing of the sodium bisulfite-treated DNA from HCC cell lines and HCC samples revealed a high percentage of hypermethylation of the CpG islands. Comparatively, the five nonneoplastic correspondent liver tissues demonstrated very low levels of methylation. To further understand the functional role of GADD45beta under-expression in HCC the GADD45beta cDNA constructed plasmid was transfected into HepG2 (p53 WT) and Hep3B (p53 null) cells. The transforming growth factor-beta was assayed by enzyme-linked immunosorbent assay, which revealed a decrease to 40% in transfectant of HepG2, but no significant change in Hep3B transfectant. Whereas, Hep3B co-transfected with p53 and GADD45beta demonstrated significantly reduced transforming growth factor-beta. The colony formation was further examined and revealed a decrease in HepG2-GADD45beta transfectant and Hep3B-p53/GADD45beta co-transfectant. These findings suggested that methylation might play a crucial role in the epigenetic regulation of GADD45beta in hepatocyte transformation that may be directed by p53 status. Thus, our results provided a deeper understanding of the molecular mechanism of GADD45beta down-regulation in HCC.

Silencing HOXD10 by Promoter Region Hypermethylation Activates ERK Signaling in Hepatocellular Carcinoma

Homeobox D10 Gene, a Candidate Tumor Suppressor, is Downregulated Through Promoter Hypermethylation and Associated with Gastric Carcinogenesis

Silencing of Hsa_circ_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation of Microrna-214-3p/ezh2 Axis

Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC/AKT/MAPK signaling pathway

Silencing of Long Noncoding RNA HOXD-AS1 Inhibits Proliferation, Cell Cycle Progression, Migration and Invasion of Hepatocellular Carcinoma Cells Through MEK/ERK Pathway.

Restoring HOXD10 Exhibits Therapeutic Potential for Ameliorating Malignant Progression and 5-Fluorouracil Resistance in Colorectal Cancer

Promoter Hypomethylation is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma.

Sox15 Methylation Inhibits Cell Proliferation Through Wnt Signaling in Hepatocellular Carcinoma

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Restoring <i>HOXD10</i> Exhibits Therapeutic Potential for Ameliorating Malignant Progression and 5-Fluorouracil Resistance in Colorectal Cancer

HOXA10 Knockdown Inhibits Proliferation, Induces Cell Cycle Arrest and Apoptosis in Hepatocellular Carcinoma Cells Through HDAC1

Epigenetic Silencing of TMEM176A Activates ERK Signaling in Human Hepatocellular Carcinoma

Relationship between promoter methylation of homeobox D10 gene and clinical prognosis of patients with cholangiocarcinoma

RASSF10 Suppresses Hepatocellular Carcinoma Growth by Activating P53 Signaling and Methylation of RASSF10 is a Docetaxel Resistant Marker

MeCP2 Drives Hepatocellular Carcinoma Progression Via Enforcing HOXD3 Promoter Methylation and Expression Through the HB-EGF/EGFR Pathway.

Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma

miR-200a-3p- and miR-181-5p-Mediated HOXB5 Upregulation Promotes HCC Progression by Transcriptional Activation of EGFR

RASSF10 is an Epigenetically Inactivated Tumor Suppressor and Independent Prognostic Factor in Hepatocellular Carcinoma

Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma

A Positive Feedback Loop of Lncrna HOXD-AS2 and SMYD3 Facilitates Hepatocellular Carcinoma Progression Via the MEK/ERK Pathway.

Hypermethylation of Growth Arrest DNA Damage-Inducible Gene 45 Β Promoter in Human Hepatocellular Carcinoma